Emory Johns Creek Hospital

Doctors:

Cletus A. Arciero MD

Bruce D Goldsweig MD

Noreen Khan MD

Seth A Rosen MD

Joseph Shelton MD

Liza J. Stapleford MD

Clinical Trials in Georgia

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Cancer Type: Esophogeal Cancer, Stomach/ Gastric Cancer, Unknown Primary

An Internet-Based Application for Improving Adherence to Endocrine Therapy among Patients with Early Stage Hormone Receptor Positive, HER2-Negative Breast Cancer
Cancer Type: Breast Cancer, Unknown Primary

An Investigational Scan (18F-rhPSMA 7.3 PET/CT) with and without Furosemide for the Reduction of Bladder Activity in Patients with Biochemically Recurrent Prostate Cancer
Cancer Type: Prostate Cancer

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing the Role of DNA Released from Tumor Cells into the Blood in Guiding the Use of Immunotherapy after Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study
Cancer Type: Bladder Cancer, Unknown Primary

Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial
Cancer Type: Melanoma